Replies to post #175119 on Biotech Values

[mcbio]

ARQL @ Needham (4/9/14):

1. CEO called ARQ092 (AKT inhibitor) "quite differentiated" from the rest of its competitors.

2. Tivantinib royalties due from Daiichi range in low to mid 20 percent range. (Was this previously known?)

3. For ARQ087 (FGFR inhibitor), ARQL is seeing stable disease as best response so far and is just getting to the dose level where they expect to see more activity.